Privately held biotech Signum Biosciences Inc. signaled its intention to play in a bigger sandbox on Wednesday by signing an agreement with GlaxoSmithKline (China) R&D Co. Ltd. to advance Signum's phosphatase screening technology, which targets the phosphoprotein phosphatase 2A (PP2A) as a key mechanism in Alzheimer's disease (AD).
